Acquisition Opportunity MedSource was acquired by Ergomed plc for 25M on Jan 1st 2020, indicating a transition in ownership and potential realignment of CRO partnerships. This creates an opening to approach Ergomed portfolio clients or legacy MedSource accounts with complementary solutions that fit their oncology and rare disease focus.

Oncology Focus Specialization in oncology clinical trials and cancer studies suggests a strong cross-sell opportunity to larger oncology CROs and biopharma with oncology pipelines, especially for sponsors seeking niche expertise, biometrics leadership, and trials in oncology.

Leadership Growth Recent leadership hires including a VP of Operations and heads of biometrics and data management indicate a growth-focused team, presenting chances to position advanced data management, statistics, and data science solutions to support expanding trial complexity.

Tech Enablement Adoption of industry tools such as SAS, AWS, Salesforce, and QuickBooks shows a tech-enabled operation. There is an opportunity to introduce integrated Sellevo/Cloud-based trial management, analytics, and financial integration services to improve efficiency and scale.

Financial Accessibility Current revenue is under one million, signaling a potential entry point for mid-market CRO services, cost-effective sponsored programs, and scalable outsourcing models that align with MedSource’s niche capabilities while targeting larger sponsors through a staged growth approach.